Evaluation of the effect of a 0.0584% hydrocortisone aceponate spray on clinical signs and skin barrier function in dogs with atopic dermatitis.
10.4142/jvs.2012.13.2.187
- Author:
Eui Hwa NAM
1
;
Seol Hee PARK
;
Ji Young JUNG
;
Seung Hee HAN
;
Hwa Young YOUN
;
Jun Seok CHAE
;
Cheol Yong HWANG
Author Information
1. College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul 151-742, Korea. cyhwang@snu.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
atopic dermatitis;
canine;
hydrocortisone aceponate;
transepidermal water loss
- MeSH:
Administration, Topical;
Animals;
Anti-Inflammatory Agents/administration & dosage/*therapeutic use;
Dermatitis, Atopic/drug therapy/pathology/*veterinary;
Dog Diseases/*drug therapy/pathology;
Dogs;
Female;
Hydrocortisone/administration & dosage/*analogs & derivatives/therapeutic use;
Male
- From:Journal of Veterinary Science
2012;13(2):187-191
- CountryRepublic of Korea
- Language:English
-
Abstract:
The purpose of this study was to evaluate the effects of a topical spray containing 0.0584% hydrocortisone aceponate (HCA) on canine atopic dermatitis (CAD) and to evaluate the skin barrier function during the treatment of CAD. Twenty-one dogs that fulfilled the diagnostic criteria for CAD were included in this study. The HCA spray was applied once a day to the lesions of all dogs for 7 or 14 days. Clinical assessment was performed before (day 0) and after treatment (day 14), and clinical responses were correlated with changes in skin barrier function. CAD severity significantly decreased after 14 days of HCA treatment based on the lesion scores (p < 0.0001), which were determined using the CAD extent and severity index (CADESI-03) and pruritus scores (p < 0.0001) calculated using a pruritus visual analog scale. Transepidermal water loss, a biomarker of skin barrier function, was significantly reduced compared to baseline (day 0) measurements (p = 0.0011). HCA spray was shown to be effective for significantly improving the condition of dogs suffering from CAD. This treatment also significantly improved cutaneous hydration and skin barrier function in the animals.
